Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Cerilliant
US Army
Express Scripts
Citi
Deloitte
Mallinckrodt
Accenture
Johnson and Johnson

Generated: May 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,595,760

« Back to Dashboard

Summary for Patent: 5,595,760
Title: Sustained release of peptides from pharmaceutical compositions
Abstract:The invention features a method of administering a peptide to a patient and delivering the peptide continuously over an extended period of time of at least three days by obtaining a solid pharmaceutical composition including a soluble, gelable salt of the peptide and up to 30 percent, by weight, of a pharmaceutically acceptable, soluble, monomeric carrier, and parenterally administering the solid composition to the patient in one injection, wherein the solid composition automatically forms a gel after interaction with the patient's bodily fluids and releases the peptide continuously within the patient over an extended period of at least three days.
Inventor(s): Cherif-Cheikh; Roland (Issy-les-Moulineaux, FR)
Assignee: Delab (Paris, FR)
Application Number:08/400,610
Patent Claim Types:
see list of patent claims
Use; Delivery; Composition; Dosage form;

Drugs Protected by US Patent 5,595,760

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Ipsen Pharma SOMATULINE DEPOT lanreotide acetate SOLUTION;SUBCUTANEOUS 022074-001 Aug 30, 2007 RX Yes Yes ➤ Sign Up ➤ Sign Up Y METHOD OF ADMINISTERING LANREOTIDE ACETATE ➤ Sign Up
Ipsen Pharma SOMATULINE DEPOT lanreotide acetate SOLUTION;SUBCUTANEOUS 022074-002 Aug 30, 2007 RX Yes Yes ➤ Sign Up ➤ Sign Up Y METHOD OF ADMINISTERING LANREOTIDE ACETATE ➤ Sign Up
Ipsen Pharma SOMATULINE DEPOT lanreotide acetate SOLUTION;SUBCUTANEOUS 022074-003 Aug 30, 2007 RX Yes Yes ➤ Sign Up ➤ Sign Up Y METHOD OF ADMINISTERING LANREOTIDE ACETATE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 5,595,760

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,660,846 Methods and apparatus for the delivery of solid drug compositions ➤ Sign Up
5,582,591 Delivery of solid drug compositions ➤ Sign Up
6,306,420 Methods and apparatus for the delivery of solid drug compositions ➤ Sign Up
5,837,276 Apparatus for the delivery of elongate solid drug compositions ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 5,595,760

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2198916 ➤ Sign Up
Brazil 9508688 ➤ Sign Up
European Patent Office 0779805 ➤ Sign Up CA 2002 00032 Denmark ➤ Sign Up
European Patent Office 0779805 ➤ Sign Up 91037 Luxembourg ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Cantor Fitzgerald
Moodys
Express Scripts
Healthtrust
Julphar
Mallinckrodt
Teva
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.